Pathophysiology and Medical Treatment of Carotid Artery Stenosis

Kailash Prasad

doi:10.1055/s-0035-1554911

International Journal of Angiology, Table of Contents

Int J Angiol 2015; 24(03): 158-172
DOI: 10.1055/s-0035-1554911

Invited Paper

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Pathophysiology and Medical Treatment of Carotid Artery Stenosis

Kailash Prasad

¹Department of Physiology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

› Author Affiliations

Abstract

Stroke is the third leading cause of mortality. Approximately 80 to 85% strokes are ischemic due to carotid artery stenosis (CAS). The prevalence of significant CAS is 7% in women and 9% in men. Severe asymptomatic CAS varies from 0 to 3.1%. Prevalence of symptomatic CAS is high in patients with peripheral arterial disease. CAS is due to atherosclerosis, the major risk factors for which include dyslipidemia, hypertension, diabetes, obesity, cigarette smoking, advanced glycation end products (AGEs) and its receptors (RAGE, soluble RAGE [sRAGE]), lack of exercise and C-reactive protein (CRP). This article discusses the basic mechanism of atherosclerosis and the mechanisms by which these risk factors induce atherosclerosis. The role of AGEs and its receptors in the development and progression of CAS has been discussed in detail. Lifestyle changes and medical treatment of CAS such as lifestyle changes, lipid-lowering agents, antihypertensive agents, antidiabetic drugs, anti-AGE therapy, measures to elevate soluble receptors of AGE (sRAGE, esRAGE). CRP-lowering agents have been discussed in detail. The drugs especially lipid-lowering agents, and antihypertensive and antidiabetic drugs suppress, regress, and slow the progression of CAS. The possible role of lowering the levels of AGEs and raising the levels of sRAGE in the treatment of CAS has been proposed. Lifestyle changes besides medical treatment have been stressed. Lifestyle changes and medical treatment not only would slow the progression of CAS but would also regress the CAS.

Keywords

carotid artery stenosis - epidemiology - pathogenesis - risk factors - treatment - oxyradicals - AGE–RAGE axis

Full Text

References

References
1 Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003; 2 (1) 43-53
2 The Intercollegiate Working Party for Stroke. National Clinical Guidelines for Stroke. 2nd ed. London: Royal College of Physicians; 2004
3 Sacco RL. Clinical practice. Extracranial carotid stenosis. N Engl J Med 2001; 345 (15) 1113-1118
4 Alpert JN. Extracranial carotid artery. Current concepts of diagnosis and management. Tex Heart Inst J 1991; 18 (2) 93-97
5 Clark TG, Murphy MF, Rothwell PM. Long term risks of stroke, myocardial infarction, and vascular death in “low risk” patients with a non-recent transient ischaemic attack. J Neurol Neurosurg Psychiatry 2003; 74 (5) 577-580
6 The European Carotid Surgery Trialists Collaborative Group. Risk of stroke in the distribution of an asymptomatic carotid artery. Lancet 1995; 345 (8944) 209-212
7 Mineva PP, Manchev IC, Hadjiev DI. Prevalence and outcome of asymptomatic carotid stenosis: a population-based ultrasonographic study. Eur J Neurol 2002; 9 (4) 383-388
8 Goessens BM, Visseren FL, Algra A, Banga JD, van der Graaf Y ; SMART Study Group. Screening for asymptomatic cardiovascular disease with noninvasive imaging in patients at high-risk and low-risk according to the European Guidelines on Cardiovascular Disease Prevention: the SMART study. J Vasc Surg 2006; 43 (3) 525-532
9 de Weerd M, Greving JP, Hedblad B , et al. Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis. Stroke 2010; 41 (6) 1294-1297
10 Barnett HJ, Taylor DW, Eliasziw M , et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998; 339 (20) 1415-1425
11 Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995; 273 (18) 1421-1428
12 Fine-Edelstein JS, Wolf PA, O'Leary DH , et al. Precursors of extracranial carotid atherosclerosis in the Framingham Study. Neurology 1994; 44 (6) 1046-1050
13 Rockman CB, Jacobowitz GR, Gagne PJ , et al. Focused screening for occult carotid artery disease: patients with known heart disease are at high risk. J Vasc Surg 2004; 39 (1) 44-51
14 Griffiths PD, Worthy S, Gholkar A. Incidental intracranial vascular pathology in patients investigated for carotid stenosis. Neuroradiology 1996; 38 (1) 25-30
15 Kappelle LJ, Eliasziw M, Fox AJ, Sharpe BL, Barnett HJ. Importance of intracranial atherosclerotic disease in patients with symptomatic stenosis of the internal carotid artery. The North American Symptomatic Carotid Endarterectomy Trail. Stroke 1999; 30 (2) 282-286
16 O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr SK ; Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340 (1) 14-22
17 Klop RB, Eikelboom BC, Taks AC. Screening of the internal carotid arteries in patients with peripheral vascular disease by colour-flow duplex scanning. Eur J Vasc Surg 1991; 5 (1) 41-45
18 Alexandrova NA, Gibson WC, Norris JW, Maggisano R. Carotid artery stenosis in peripheral vascular disease. J Vasc Surg 1996; 23 (4) 645-649
19 Ahmed B, Al-Khaffaf H. Prevalence of significant asymptomatic carotid artery disease in patients with peripheral vascular disease: a meta-analysis. Eur J Vasc Endovasc Surg 2009; 37 (3) 262-271
20 Bavil AS, Ghabili K, Daneshmand SE , et al. Prevalence of significant carotid artery stenosis in Iranian patients with peripheral arterial disease. Vasc Health Risk Manag 2011; 7: 629-632
21 Tanimoto S, Ikari Y, Tanabe K , et al. Prevalence of carotid artery stenosis in patients with coronary artery disease in Japanese population. Stroke 2005; 36 (10) 2094-2098
22 Kallikazaros I, Tsioufis C, Sideris S, Stefanadis C, Toutouzas P. Carotid artery disease as a marker for the presence of severe coronary artery disease in patients evaluated for chest pain. Stroke 1999; 30 (5) 1002-1007
23 Steinvil A, Sadeh B, Arbel Y , et al. Prevalence and predictors of concomitant carotid and coronary artery atherosclerotic disease. J Am Coll Cardiol 2011; 57 (7) 779-783
24 Qureshi AI, Alexandrov AV, Tegeler CH, Hobson II RW, Dennis Baker J, Hopkins LN ; American Society of Neuroimaging; Society of Vascular and Interventional Neurology. Guidelines for screening of extracranial carotid artery disease: a statement for healthcare professionals from the multidisciplinary practice guidelines committee of the American Society of Neuroimaging; cosponsored by the Society of Vascular and Interventional Neurology. J Neuroimaging 2007; 17 (1) 19-47
25 Mathiesen EB, Joakimsen O, Bønaa KH. Prevalence of and risk factors associated with carotid artery stenosis: the Tromsø Study. Cerebrovasc Dis 2001; 12 (1) 44-51
26 Prasad K. Pathophysiology of atherosclerosis. In: Chang JB, Olsen ER, Prasad K, Sumpio BE, , eds. Textbook of Angiology. New York, NY: Springer Verlag; 2000: 85-105
27 Yamazaki M, Uchiyama S. Pathophysiology of carotid stenosis [in Japanese]. Brain Nerve 2010; 62 (12) 1269-1275
28 Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94 (6) 2493-2503
29 Naghavi M, Libby P, Falk E , et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108 (14) 1664-1672
30 Wahlgren CM, Zheng W, Shaalan W, Tang J, Bassiouny HS. Human carotid plaque calcification and vulnerability. Relationship between degree of plaque calcification, fibrous cap inflammatory gene expression and symptomatology. Cerebrovasc Dis 2009; 27 (2) 193-200
31 Shaalan WE, Cheng H, Gewertz B , et al. Degree of carotid plaque calcification in relation to symptomatic outcome and plaque inflammation. J Vasc Surg 2004; 40 (2) 262-269
32 Ku DN, Giddens DP, Zarins CK, Glagov S. Pulsatile flow and atherosclerosis in the human carotid bifurcation. Positive correlation between plaque location and low oscillating shear stress. Arteriosclerosis 1985; 5 (3) 293-302
33 Zarins CK, Giddens DP, Bharadvaj BK, Sottiurai VS, Mabon RF, Glagov S. Carotid bifurcation atherosclerosis. Quantitative correlation of plaque localization with flow velocity profiles and wall shear stress. Circ Res 1983; 53 (4) 502-514
34 Lind L, Andersson J, Larsson A, Sandhagen B. Shear stress in the common carotid artery is related to both intima-media thickness and echogenecity. The Prospective Investigation of the Vasculature in Uppsala Seniors study. Clin Hemorheol Microcirc 2009; 43 (4) 299-308
35 Mauriello A, Sangiorgi GM, Virmani R , et al. A pathobiologic link between risk factors profile and morphological markers of carotid instability. Atherosclerosis 2010; 208 (2) 572-580
36 Prasad K, Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. Am Heart J 1993; 125 (4) 958-973
37 Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 1999; 99 (10) 1355-1362
38 Prasad K, Kalra J, Lee P. Oxygen free radicals as a mechanism of hypercholesterolemic atherosclerosis: effect of probucol. Int J Angiol 1994; 3: 100-112
39 Steinberg D. Antioxidants and atherosclerosis. A current assessment. Circulation 1991; 84 (3) 1420-1425
40 Steinberg D. Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop: September 5–6, 1991, Bethesda, Maryland. Circulation 1992; 85 (6) 2337-2344
41 Willam C, Schindler R, Frei U, Eckardt KU. Increases in oxygen tension stimulate expression of ICAM-1 and VCAM-1 on human endothelial cells. Am J Physiol 1999; 276 (6 Pt 2) H2044-H2052
42 Chiu JJ, Wung BS, Shyy JY-J, Hsieh HJ, Wang DL. Reactive oxygen species are involved in shear stress-induced intercellular adhesion molecule-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17 (12) 3570-3577
43 Fraticelli A, Serrano Jr CV, Bochner BS, Capogrossi MC, Zweier JL. Hydrogen peroxide and superoxide modulate leukocyte adhesion molecule expression and leukocyte endothelial adhesion. Biochim Biophys Acta 1996; 1310 (3) 251-259
44 Martin A, Foxall T, Blumberg JB, Meydani M. Vitamin E inhibits low-density lipoprotein-induced adhesion of monocytes to human aortic endothelial cells in vitro. Arterioscler Thromb Vasc Biol 1997; 17 (3) 429-436
45 Cushing SD, Berliner JA, Valente AJ , et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A 1990; 87 (13) 5134-5138
46 Steinberg D. Oxidized low density lipoprotein—an extreme example of lipoprotein heterogeneity. Isr J Med Sci 1996; 32 (6) 469-472
47 Wang GP, Deng ZD, Ni J, Qu ZL. Oxidized low density lipoprotein and very low density lipoprotein enhance expression of monocyte chemoattractant protein-1 in rabbit peritoneal exudate macrophages. Atherosclerosis 1997; 133 (1) 31-36
48 Navab M, Imes SS, Hama SY , et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88 (6) 2039-2046
49 Hashimoto K, Kataoka N, Nakamura E, Tsujioka K, Kajiya F. Oxidized LDL specifically promotes the initiation of monocyte invasion during transendothelial migration with upregulated PECAM-1 and downregulated VE-cadherin on endothelial junctions. Atherosclerosis 2007; 194 (2) e9-e17
50 Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A 1979; 76 (1) 333-337
51 Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93 (2) 229-240
52 Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of biological modified low density lipoprotein. Atherosclerosis 1983; 3 (2) 149-159
53 Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996; 98 (11) 2572-2579
54 Phan SH, McGarry BM, Loeffler KM, Kunkel SL. Regulation of macrophage-derived fibroblast growth factor release by arachidonate metabolites. J Leukoc Biol 1987; 42 (2) 106-113
55 Raitakari OT, Juonala M, Kähönen M , et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003; 290 (17) 2277-2283
56 Warnholtz A, Wendt M, August M, Münzel T. Clinical aspects of reactive oxygen and nitrogen species. Biochem Soc Symp 2004; 71 (71) 121-133
57 White CR, Darley-Usmar V, Berrington WR , et al. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci U S A 1996; 93 (16) 8745-8749
58 Liu H-R, Tao L, Gao E , et al. Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation—a novel mechanism for the cardioprotective effects of PPAR agonists. Cardiovasc Res 2009; 81 (2) 344-352
59 Zhu X, Lee JY, Timmins JM , et al. Increased cellular free cholesterol in macrophage specific Abca 1 knock-out mice enhances proinflammatory response of macrophage. J Biol Chem 2008; 283: 2930-2294
60 Yang D, Elner SG, Bian ZM, Till GO, Petty HR, Elner VM. Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Exp Eye Res 2007; 85 (4) 462-472
61 Prasad K, Mantha SV, Kalra J, Lee P. Prevention of hypercholesterolemic atherosclerosis by garlic, an antioxidant. J Cardiovasc Pharmacol Therapeut 1997; 2 (4) 309-319
62 Prasad K. Hypocholesterolemic and antiatherosclerotic effect of flax lignan complex isolated from flaxseed. Atherosclerosis 2005; 179 (2) 269-275
63 O'Donnell RW, Johnson DK, Ziegler LM, DiMattina AJ, Stone RI, Holland JA. Endothelial NADPH oxidase: mechanism of activation by low-density lipoprotein. Endothelium 2003; 10 (6) 291-297
64 Heinloth A, Heermeier K, Raff U, Wanner C, Galle J. Stimulation of NADPH oxidase by oxidized low-density lipoprotein induces proliferation of human vascular endothelial cells. J Am Soc Nephrol 2000; 11 (10) 1819-1825
65 Smalley DM, Lin JH, Curtis ML, Kobari Y, Stemerman MB, Pritchard Jr KA. Native LDL increases endothelial cell adhesiveness by inducing intercellular adhesion molecule-1. Arterioscler Thromb Vasc Biol 1996; 16 (4) 585-590
66 Allen S, Khan S, Al-Mohanna F, Batten P, Yacoub M. Native low density lipoprotein-induced calcium transients trigger VCAM-1 and E-selectin expression in cultured human vascular endothelial cells. J Clin Invest 1998; 101 (5) 1064-1075
67 Zhu HL, Xia M, Hou MJ, Tang ZH, Zheng PY, Ling WH. Effects of LOX-1 on expression of adhesion molecules induced by ox-LDL in HUVECs [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi 2005; 33 (8) 743-747
68 Peshavariya H, Dusting GJ, Di Bartolo B, Rye KA, Barter PJ, Jiang F. Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts. Free Radic Res 2009; 43 (8) 772-782
69 Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15 (11) 1987-1994
70 Calabresi L, Franceschini G, Sirtori CR , et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun 1997; 238 (1) 61-65
71 Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 2004; 318 (3) 680-683
72 Eggesbø JB, Hjermann I, Høstmark AT, Joø GB, Kierulf P. Lipopolysaccharide-induced monocyte procoagulant activity, fibrinopeptide A, and PAI-I levels in persons with high or low levels of HDL-lipoprotein. Thromb Res 1993; 70 (2) 161-171
73 Tölle M, Pawlak A, Schuchardt M , et al. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol 2008; 28 (8) 1542-1548
74 Kim YS, Sung HJ, Son SJ , et al. Triglyceride (TG) down-regulates expression of MCP-1 and CCR2 in PMA-derived THP-1 macrophages. Genes and Genomics 2013; 35 (1) 125-130
75 Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003; 31 (Pt 5) 1066-1069
76 Wang L, Gill R, Pedersen TL, Higgins LJ, Newman JW, Rutledge JC. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res 2009; 50 (2) 204-213
77 Eiselein L, Wilson DW, Lamé MW, Rutledge JC. Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis. Am J Physiol Heart Circ Physiol 2007; 292 (6) H2745-H2753
78 Wang YI, Bettaieb A, Sun C , et al. Triglyceride-rich lipoprotein modulates endothelial vascular cell adhesion molecule (VCAM)-1 expression via differential regulation of endoplasmic reticulum stress. PLoS ONE 2013; 8 (10) e78322
79 Skartlien AH, Lyberg-Beckmann S, Holme I, Hjermann I, Prydz H. Effect of alteration in triglyceride levels on factor VII-phospholipid complexes in plasma. Arteriosclerosis 1989; 9 (6) 798-801
80 Negri M, Arigliano PL, Talamini G, Carlini S, Manzato F, Bonadonna G. Levels of plasma factor VII and factor VII activated forms as a function of plasma triglyceride levels. Atherosclerosis 1993; 99 (1) 55-61
81 Simpson HCR, Mann JI, Meade TW, Chakrabarti R, Stirling Y, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1983; 1 (8328) 786-790
82 Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313 (25) 1557-1563
83 Vanschoonbeek K, Feijge MA, Saris WH, de Maat MP, Heemskerk JW. Plasma triacylglycerol and coagulation factor concentrations predict the anticoagulant effect of dietary fish oil in overweight subjects. J Nutr 2007; 137 (1) 7-13
84 Kitiyakara C, Wilcox CS. Antioxidants for hypertension. Curr Opin Nephrol Hypertens 1998; 7 (5) 531-538
85 Zalba G, Beaumont FJ, San José G , et al. Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 2000; 35 (5) 1055-1061
86 Wu R, Millette E, Wu L, de Champlain J. Enhanced superoxide anion formation in vascular tissues from spontaneously hypertensive and desoxycorticosterone acetate-salt hypertensive rats. J Hypertens 2001; 19 (4) 741-748
87 Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 2004; 122 (4) 339-352
88 Welch WJ. Intrarenal oxygen and hypertension. Clin Exp Pharmacol Physiol 2006; 33 (10) 1002-1005
89 Redón J, Oliva MR, Tormos C , et al. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003; 41 (5) 1096-1101
90 Manning Jr RD, Meng S, Tian N. Renal and vascular oxidative stress and salt-sensitivity of arterial pressure. Acta Physiol Scand 2003; 179 (3) 243-250
91 Houston MC. Nutraceuticals, vitamins, antioxidants, and minerals in the prevention and treatment of hypertension. Prog Cardiovasc Dis 2005; 47 (6) 396-449
92 Lacy F, Kailasam MT, O'Connor DT, Schmid-Schönbein GW, Parmer RJ. Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. Hypertension 2000; 36 (5) 878-884
93 Sagar S, Kallo IJ, Kaul N, Ganguly NK, Sharma BK. Oxygen free radicals in essential hypertension. Mol Cell Biochem 1992; 111 (1–2) 103-108
94 Yasunari K, Maeda K, Nakamura M, Yoshikawa J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Hypertension 2002; 39 (3) 777-780
95 Fortuño A, Oliván S, Beloqui O , et al. Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens 2004; 22 (11) 2169-2175
96 Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002; 346 (25) 1954-1962
97 Lip GY, Edmunds E, Nuttall SL, Landray MJ, Blann AD, Beevers DG. Oxidative stress in malignant and non-malignant phase hypertension. J Hum Hypertens 2002; 16 (5) 333-336
98 Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am 2009; 93 (3) 621-635
99 Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004; 13 (1) 93-99
100 Addabbo F, Montagnani M, Goligorsky MS. Mitochondria and reactive oxygen species. Hypertension 2009; 53 (6) 885-892
101 Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension. J Hum Hypertens 2005; 19 (2) 149-154
102 Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38 (3) 399-403
103 Dalekos GN, Elisaf M, Bairaktari E, Tsolas O, Siamopoulos KC. Increased serum levels of interleukin-1β in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients?. J Lab Clin Med 1997; 129 (3) 300-308
104 Lusis AJ. Atherosclerosis. Nature 2000; 407 (6801) 233-241
105 Shalia KK, Mashru MR, Vasvani JB, Mokal RA, Mithbawkar SM, Thakur PK. Circulating levels of cell adhesion molecules in hypertension. Indian J Clin Biochem 2009; 24 (4) 388-397
106 Malmqvist K, Wallén HN, Held C, Kahan T. Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy. J Hypertens 2002; 20 (8) 1563-1569
107 Itoh T, Nagaya N, Ishibashi-Ueda H , et al. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology 2006; 11 (2) 158-163
108 Koh KK, Ahn JY, Han SH , et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42 (5) 905-910
109 Deo R, Khera A, McGuire DK , et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 2004; 44 (9) 1812-1818
110 Parissis JT, Venetsanou KF, Kalantzi MV, Mentzikof DD, Karas SM. Serum profiles of granulocyte-macrophage colony-stimulating factor and C-C chemokines in hypertensive patients with or without significant hyperlipidemia. Am J Cardiol 2000; 85 (6) 777-779 , A9
111 Tell GS, Polak JF, Ward BJ, Kittner SJ, Savage PJ, Robbins J ; The Cardiovascular Health Study (CHS) Collaborative Research Group. Relation of smoking with carotid artery wall thickness and stenosis in older adults. The Cardiovascular Health Study. Circulation 1994; 90 (6) 2905-2908
112 Mast H, Thompson JLP, Lin I-F , et al. Cigarette smoking as a determinant of high-grade carotid artery stenosis in Hispanic, black, and white patients with stroke or transient ischemic attack. Stroke 1998; 29 (5) 908-912
113 Kalra J, Chaudhary AK, Prasad K. Increased production of oxygen free radicals in cigarette smokers. Int J Exp Pathol 1991; 72 (1) 1-7
114 Pryor WA, Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann N Y Acad Sci 1993; 686: 12-27 , discussion 27–28
115 Kayyali US, Budhiraja R, Pennella CM , et al. Upregulation of xanthine oxidase by tobacco smoke condensate in pulmonary endothelial cells. Toxicol Appl Pharmacol 2003; 188 (1) 59-68
116 Nicholl ID, Bucala R. Advanced glycation endproducts and cigarette smoking. Cell Mol Biol (Noisy-le-grand) 1998; 44 (7) 1025-1033
117 Cerami C, Founds H, Nicholl I , et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A 1997; 94 (25) 13915-13920
118 Shah AA, Khand F, Khand TU. Effect of smoking on serum xanthine oxidase, malondialdehyde, ascorbic acid and α-tocopherol levels in healthy male subjects. Pak J Med Sci 2015; 31 (1) 146-149
119 Totti III N, McCusker KT, Campbell EJ, Griffin GL, Senior RM. Nicotine is chemotactic for neutrophils and enhances neutrophil responsiveness to chemotactic peptides. Science 1984; 223 (4632) 169-171
120 Assmann G, Schulte H, Schriewer H. The effects of cigarette smoking on serum levels of HDL cholesterol and HDL apolipoprotein A-I. Findings of a prospective epidemiological study on employees of several companies in Westphalia, West Germany. J Clin Chem Clin Biochem 1984; 22 (6) 397-402
121 Kokaze A, Ishikawa M, Matsunaga N , et al. Difference in effects of cigarette smoking or alcohol consumption on serum non-high-density lipoprotein cholesterol levels is related to mitochondrial DNA 5178 C/A polymorphism in middle-aged Japanese men: a cross-sectional study. J Physiol Anthropol 2014; 33: 1
122 McDermott DH, Yang Q, Kathiresan S , et al. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 2005; 112 (8) 1113-1120
123 Prasad K, Dhar I. Role of advanced glycation end products and its receptors in the pathogenesis of cigarette smoke-induced cardiovascular disease. Int J Angiol 2015; 24 (2) 75-80
124 Prasad K. Soluble receptor for advanced glycation end products (sRAGE) and cardiovascular disease. Int J Angiol 2006; 15: 57-68
125 Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000; 1498 (2–3) 99-111
126 Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84 (5) 489-497
127 Braquet P, Hosford D, Braquet M, Bourgain R, Bussolino F. Role of cytokines and platelet-activating factor in microvascular immune injury. Int Arch Allergy Appl Immunol 1989; 88 (1–2) 88-100
128 Yuo A, Kitagawa S, Kasahara T, Matsushima K, Saito M, Takaku F. Stimulation and priming of human neutrophils by interleukin-8: cooperation with tumor necrosis factor and colony-stimulating factors. Blood 1991; 78 (10) 2708-2714
129 Anil S, Preethanath RS, Alasqah M, Mokeem SA, Anand PS. Increased levels of serum and gingival crevicular fluid monocyte chemoattractant protein-1 in smokers with periodontitis. J Periodontol 2013; 84 (9) e23-e28
130 Köttstorfer J, Kaiser G, Thomas A , et al. The influence of non-osteogenic factors on the expression of M-CSF and VEGF during fracture healing. Injury 2013; 44 (7) 930-934
131 Al-Ghurabi BH. Impact of smoking on the IL-β, IL-8, IL-10, IL-17 and TNF-α production in chronic periodontitis patients. J Asian Sci Res. 2013; 3 (5) 462-470
132 Scott DA, Palmer RM. The influence of tobacco smoking on adhesion molecule profiles. Tob Induc Dis 2002; 1 (1) 7-25
133 Cavusoglu Y, Timuralp B, Us T , et al. Cigarette smoking increases plasma concentrations of vascular cell adhesion molecule-1 in patients with coronary artery disease. Angiology 2004; 55 (4) 397-402
134 Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Rozek MM. Pathogenesis of the atherosclerotic lesion. Implications for diabetes mellitus. Diabetes Care 1992; 15 (9) 1156-1167
135 Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48 (5) 937-942
136 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329 (14) 977-986
137 Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol 2003; 552 (Pt 2) 335-344
138 Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr Opin Clin Nutr Metab Care 2002; 5 (5) 561-568
139 Inoguchi T, Li P, Umeda F , et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C—dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49 (11) 1939-1945
140 Banerjee D, Sharma P. Dual effects of glucose on macrophage NADPH-oxidase activity: a possible link between diabetes and tuberculosis. Oxid Antioxid Med Sci 2012; 1 (2) 91-96
141 Wolff SP. Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull 1993; 49 (3) 642-652
142 Elrick H, Stimmler L, Hlad Jr CJ, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24: 1076-1082
143 May JM, de Haën C. Insulin-stimulated intracellular hydrogen peroxide production in rat epididymal fat cells. J Biol Chem 1979; 254 (7) 2214-2220
144 Goldstein BJ, Mahadev K, Wu X, Zhu L, Motoshima H. Role of insulin-induced reactive oxygen species in the insulin signaling pathway. Antioxid Redox Signal 2005; 7 (7–8) 1021-1031
145 Maples KR, Mason RP. Free radical metabolite of uric acid. J Biol Chem 1988; 263 (4) 1709-1712
146 Vásquez-Vivar J, Santos AM, Junqueira VB, Augusto O. Peroxynitrite-mediated formation of free radicals in human plasma: EPR detection of ascorbyl, albumin-thiyl and uric acid-derived free radicals. Biochem J 1996; 314 (Pt 3) 869-876
147 Bagnati M, Perugini C, Cau C, Bordone R, Albano E, Bellomo G. When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. Biochem J 1999; 340 (Pt 1) 143-152
148 Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992; 23: 1-34
149 Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318 (20) 1315-1321
150 Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 70 (2) 138-151
151 Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995; 34 (34) 10872-10878
152 Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 1985; 34 (9) 938-941
153 Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232 (4758) 1629-1632
154 Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A 1993; 90 (14) 6434-6438
155 Steinbrecher UP, Witztum JL. Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984; 33 (2) 130-134
156 Neeper M, Schmidt AM, Brett J , et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267 (21) 14998-15004
157 Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108 (7) 949-955
158 Tam XHL, Shiu SWM, Leng L, Bucala R, Betteridge DJ, Tan KCB. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin Sci (Lond) 2011; 120 (2) 81-89
159 Yonekura H, Yamamoto Y, Sakurai S , et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370 (Pt 3) 1097-1109
160 Koyama H, Shoji T, Yokoyama H , et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25 (12) 2587-2593
161 Koyama H, Yamamoto H, Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med 2007; 13 (11–12) 625-635
162 Park L, Raman KG, Lee KJ , et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4 (9) 1025-1031
163 Tanji N, Markowitz GS, Fu C , et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000; 11 (9) 1656-1666
164 Brett J, Schmidt AM, Yan SD , et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993; 143 (6) 1699-1712
165 Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280 (5) E685-E694
166 Hofmann MA, Drury S, Fu C , et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97 (7) 889-901
167 Reznikov LL, Waksman J, Azam T , et al. Effect of advanced glycation end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells. Clin Nephrol 2004; 61 (5) 324-336
168 Schmidt AM, Hori O, Chen JX , et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96 (3) 1395-1403
169 Wautier JL, Zoukourian C, Chappey O , et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97 (1) 238-243
170 Esposito C, Gerlach H, Brett J, Stern D, Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989; 170 (4) 1387-1407
171 Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 1993; 91 (5) 2155-2168
172 Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A 1992; 89 (24) 12043-12047
173 Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988; 240 (4858) 1546-1548
174 Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci U S A 1990; 87 (22) 9010-9014
175 Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992; 90 (2) 439-446
176 Klein RL, Laimins M, Lopes-Virella MF. Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes 1995; 44 (9) 1093-1098
177 Sakata N, Meng J, Takebayashi S. Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J Atheroscler Thromb 2000; 7 (3) 169-176
178 Sakaguchi T, Yan SF, Yan SD , et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111 (7) 959-972
179 Zhou Z, Wang K, Penn MS , et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 2003; 107 (17) 2238-2243
180 Wendt TM, Bucciarelli LG, Lu X , et al. Accelerated atherosclerosis and vascular inflammation develop in apo-E null mice with type 2 diabetes. Circulation 2000; 102 (Suppl): II-231 [abstract]
181 Kislinger T, Tanji N, Wendt T , et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2001; 21 (6) 905-910
182 McNair ED, Wells CR, Qureshi AM , et al. Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients. Int J Angiol 2009; 18 (4) 187-192
183 McNair ED, Wells CR, Mabood Qureshi A , et al. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. Clin Cardiol 2010; 33 (11) 678-685
184 Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994; 43 (9) 1122-1129
185 Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47 (6) 859-866
186 Kawano M, Koshikawa T, Kanzaki T, Morisaki N, Saito Y, Yoshida S. Diabetes mellitus induces accelerated growth of aortic smooth muscle cells: association with overexpression of PDGF β-receptors. Eur J Clin Invest 1993; 23 (2) 84-90
187 Nabel EG, Shum L, Pompili VJ , et al. Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A 1993; 90 (22) 10759-10763
188 Bloomgarden ZT. Obesity and diabetes. Diabetes Care 2000; 23 (10) 1584-1590
189 Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res 2010; 33 (5) 386-393
190 Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444 (7121) 840-846
191 Rost NS, Wolf PA, Kase CS , et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001; 32 (11) 2575-2579
192 Mullenix PS, Steele SR, Martin MJ, Starnes BW, Andersen CA. C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis. Arch Surg 2007; 142 (11) 1066-1071
193 Xiao-Jun W, Wei L, Dong-Yang X, Yi-ming Z, Dang-Ming X, Xiao-Jun W. Correlation study of carotid atherosclerosis and serum high sensitivity C - reactive protein levels in elderly hypertensive patients. Heart 2012; 98 (Suppl. 02) E1-E319
194 Gröschel K, Ernemann U, Larsen J , et al. Preprocedural C-reactive protein levels predict stroke and death in patients undergoing carotid stenting. AJNR Am J Neuroradiol 2007; 28 (9) 1743-1746
195 Prasad K. C-reactive protein increases oxygen radical generation by neutrophils. J Cardiovasc Pharmacol Ther 2004; 9 (3) 203-209
196 Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006; 24 (1) 33-50
197 Hobson II RW, Mackey WC, Ascher E , et al; Society for Vascular Surgery. Management of atherosclerotic carotid artery disease: clinical practice guidelines of the Society for Vascular Surgery. J Vasc Surg 2008; 48 (2) 480-486
198 Herder M, Arntzen KA, Johnsen SH, Eggen AE, Mathiesen EB. Long-term use of lipid-lowering drugs slows progression of carotid atherosclerosis: the Tromso study 1994 to 2008. Arterioscler Thromb Vasc Biol 2013; 33 (4) 858-862
199 Prasad K. Do statins have a role in reduction/prevention of post-PCI restenosis?. Cardiovasc Ther 2013; 31 (1) 12-26
200 Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118
201 Cuspidi C, Negri F, Giudici V, Capra A, Sala C. Effects of antihypertensive drugs on carotid intima-media thickness: Focus on angiotensin II receptor blockers. A review of randomized, controlled trials. Integr Blood Press Control 2009; 2: 1-8
202 Johnson CT, Brewster LP. Carotid artery intima-media thickness and the renin-angiotensin system. Hosp Pract (1995) 2013; 41 (2) 54-61
203 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. U.S. Department of Health and Human Services. National Heart, Lung, and Blood Institute; 2004
204 Khan NA, McAlister FA, Lewanczuk RZ , et al. The 2005 Canadian Hypertention Education Program recommendation for the management of hypertension: part II-Therapy. Can J Cardiol 2006; 22 (7) 583-593
205 Mazzone T. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention. Am J Med 2007; 120 (9, Suppl 2): S26-S32
206 Mazzone T, Meyer PM, Feinstein SB , et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296 (21) 2572-2581
207 Schindler TH, Cadenas J, Facta AD , et al. Improvement in coronary endothelial function is independently associated with a slowed progression of coronary artery calcification in type 2 diabetes mellitus. Eur Heart J 2009; 30 (24) 3064-3073
208 Bianchi C, Miccoli R, Daniele G, Penno G, Del Prato S. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. Diabetes Care 2009; 32 (Suppl. 02) S342-S348
209 Esposito K, Giugliano D, Nappo F, Marfella R ; Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110 (2) 214-219
210 Vlassara H, Cai W, Crandall J , et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 2002; 99 (24) 15596-15601
211 Birlouez-Aragon I, Saavedra G, Tessier FJ , et al. A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr 2010; 91 (5) 1220-1226
212 Kass DA, Shapiro EP, Kawaguchi M , et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104 (13) 1464-1470
213 Salama ME, EL-Damarawi MA, Salama AF. A comparison between the impact of two different exercise protocols on advanced glycation end products in type 2 diabetic rats. Life Sci J 2013; 10 (3) 860-869
214 Choi KM, Han KA, Ahn HJ , et al. Effects of exercise on sRAGE levels and cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled trial. J Clin Endocrinol Metab 2012; 97 (10) 3751-3758
215 Lam JK, Wang Y, Shiu SW, Wong Y, Betteridge DJ, Tan KC. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE). Diabet Med 2013; 30 (6) 702-709
216 Irani M, Minkoff H, Seifer DB, Merhi Z. Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS. J Clin Endocrinol Metab 2014; 99 (5) E886-E890
217 Tam HL, Shiu SW, Wong Y, Chow WS, Betteridge DJ, Tan KC. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 2010; 209 (1) 173-177
218 Nozue T, Yamagishi S-I, Takeuchi M , et al. Effects of statins on the serum soluble receptor forms of advanced glycation end products and the association with coronary atherosclerosis in patients with angina pectoris. Int J Clin Metab Endocrin. 2014; 4: 47-62
219 Forbes JM, Thorpe SR, Thallas-Bonke V , et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005; 16 (8) 2363-2372
220 Plenge JK, Hernandez TL, Weil KM , et al, Simvastatin lowers C-reactive protein within 14 days: An effect independent of low density lipoprotein cholesterol reduction. Circulation 2002; 106: 1447-1452
221 Azen SP, Qian D, Mack WJ , et al. Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. Circulation 1996; 94 (10) 2369-2372
222 Kritchevsky SB, Shimakawa T, Tell GS , et al. Dietary antioxidants and carotid artery wall thickness. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995; 92 (8) 2142-2150
223 Devaraj S, Tang R, Adams-Huet B , et al. Effect of high-dose α-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am J Clin Nutr 2007; 86 (5) 1392-1398
224 McQuillan BM, Hung J, Beilby JP, Nidorf M, Thompson PL ; The Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Antioxidant vitamins and the risk of carotid atherosclerosis. The Perth Carotid Ultrasound Disease Assessment study (CUDAS). J Am Coll Cardiol 2001; 38 (7) 1788-1794
225 Karppi J, Kurl S, Ronkainen K, Kauhanen J, Laukkanen JA. Serum carotenoids reduce progression of early atherosclerosis in the carotid artery wall among Eastern Finnish men. PLoS ONE 2013; 8 (5) e64107
226 Gale CR, Ashurst HE, Powers HJ, Martyn CN. Antioxidant vitamin status and carotid atherosclerosis in the elderly. Am J Clin Nutr 2001; 74 (3) 402-408
227 Tomeo AC, Geller M, Watkins TR, Gapor A, Bierenbaum ML. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. Lipids 1995; 30 (12) 1179-1183
228 Aviram M, Rosenblat M, Gaitini D , et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr 2004; 23 (3) 423-433
229 Burton GW, Ingold KU. Vitamin E: application of the principles of physical organic chemistry to the exploration of its structure and function. Acc Chem Res 1986; 19: 194-201
230 Bowry VW, Ingold KU, Stocker R. Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant. Biochem J 1992; 288 (Pt 2) 341-344
231 Doba T, Burton GW, Ingold KU. Antioxidant and co-antioxidant activity of vitamin C. The effect of vitamin C, either alone or in the presence of vitamin E or a water-soluble vitamin E analogue, upon the peroxidation of aqueous multilamellar phospholipid liposomes. Biochim Biophys Acta 1985; 835 (2) 298-303
232 Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke 2009; 40 (10) e573-e583
233 Selim MH, Molina CA. Medical versus surgical treatment of asymptomatic carotid stenosis: the ever-changing nature of evidence-based medicine. Stroke 2011; 42 (4) 1156-1157